KINNATE BIOPHARMA INC's ticker is KNTE and the CUSIP is 49705R105. A total of 60 filers reported holding KINNATE BIOPHARMA INC in Q3 2023. The put-call ratio across all filers is 0.76 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,037,890 | -52.6% | 741,350 | +2.5% | 0.00% | – |
Q2 2023 | $2,190,696 | -84.6% | 723,002 | -68.2% | 0.00% | – |
Q1 2023 | $14,231,934 | -0.1% | 2,277,109 | -2.5% | 0.00% | – |
Q4 2022 | $14,248,489 | -47.6% | 2,335,818 | +2.6% | 0.00% | -100.0% |
Q3 2022 | $27,209,000 | -6.2% | 2,276,816 | -1.0% | 0.00% | 0.0% |
Q2 2022 | $28,996,000 | +25.3% | 2,299,544 | +11.9% | 0.00% | 0.0% |
Q1 2022 | $23,143,000 | -36.2% | 2,055,224 | +0.4% | 0.00% | 0.0% |
Q4 2021 | $36,273,000 | -15.9% | 2,047,035 | +9.2% | 0.00% | 0.0% |
Q3 2021 | $43,148,000 | +45.5% | 1,874,361 | +47.2% | 0.00% | 0.0% |
Q2 2021 | $29,648,000 | -21.4% | 1,273,529 | +5.2% | 0.00% | 0.0% |
Q1 2021 | $37,710,000 | +206.2% | 1,210,198 | +291.0% | 0.00% | – |
Q4 2020 | $12,314,000 | – | 309,544 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Foresite Capital Management IV, LLC | 9,671,643 | $225,156,000 | 30.44% |
Vida Ventures Advisors, LLC | 2,747,433 | $63,960,000 | 16.04% |
Foresite Capital Management V, LLC | 875,001 | $20,370,000 | 8.01% |
VR Adviser, LLC | 1,473,014 | $34,292,000 | 4.16% |
Logos Global Management LP | 1,329,602 | $30,953,000 | 2.60% |
RA Capital Management | 3,593,052 | $83,646,000 | 1.34% |
Orbimed Advisors | 3,847,929 | $89,580,000 | 0.91% |
Boxer Capital, LLC | 1,065,939 | $24,815,000 | 0.88% |
HARVARD MANAGEMENT CO INC | 498,001 | $11,593,000 | 0.67% |
HighVista Strategies LLC | 33,391 | $777,000 | 0.55% |